RxDoctor Payments Data

Ananias Ebilane, MD

General Practice · Hawthorne, CANPI 1265611362

Payments from drug & device makers

$780in general payments, 2019–2025

Across 35 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$209
  • Lilly USA, LLC$143
  • Astellas Pharma US Inc$112
  • Boehringer Ingelheim$111
  • Amarin Pharma, Inc.$52
  • Pfizer$46
  • plus $107 from 4 others

What the payments were for

  • Food & beverage$69189%
  • Education$8911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$780 in reported general payments places this provider in the 75th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$51,243
Medicare patients
93
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$81,155
JardianceEmpagliflozin95$78,772
OzempicSemaglutide61$70,272
JanuviaSitagliptin Phosphate69$70,165
TrulicityDulaglutide21$37,963
MyrbetriqMirabegron66$37,734
FarxigaDapagliflozin Propanediol31$33,003
TradjentaLinagliptin38$32,291
XareltoRivaroxaban12$16,660
Tresiba Flextouch U-100Insulin Degludec14$8,326
Janumet XrSitagliptin Phos/Metformin Hcl11$7,146
SynjardyEmpagliflozin/Metformin Hcl12$6,486
Atorvastatin Calcium594$5,524
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$5,481
Nano 2nd Gen Pen NeedlePen Needle, Diabetic52$4,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$111$117,548145 claims
PfizerEliquis$46$81,15596 claims
Novo NordiskOzempic$41$70,27261 claims
Lilly USA, LLCTrulicity$143$37,96321 claims
Astellas Pharma US IncMyrbetriq$112$37,73466 claims
AstraZenecaFarxiga$15$33,00331 claims
Johnson & JohnsonXarelto$209$16,66012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 12,963 general practice providers in California.

Other general practice in Hawthorne

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →